BFC Planning, Inc.’s CRISPR Therapeutics CRSP Stock Holding History

BFC Planning, Inc.’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$112K	Sell	2,018 -1,088	-35%	-$58.7K	﹤0.01%	1183
2026 Q2	$169K	Buy	3,106 +1,547	+99%	+$81.5K	0.01%	1000
2026 Q1	$74.2K	Sell	1,559 -93	-6%	-$4.9K	﹤0.01%	1201
2025 Q4	$86.6K	Sell	1,652 -2	-0.1%	-$120	﹤0.01%	1163
2025 Q3	$107K	Hold	1,654	–	–	0.01%	901
2025 Q2	$80.5K	Buy	1,654 +39	+2%	+$1.51K	0.01%	969
2025 Q1	$55K	Buy	1,615 +45	+3%	+$1.91K	﹤0.01%	1072
2024 Q4	$61.8K	Buy	1,570 +25	+2%	+$1.18K	0.01%	1023
2024 Q3	$72.6K	Buy	+1,545	New	+$78.4K	0.01%	982

Other funds holding CRSP

ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

BFC Planning, Inc.'s CRSP Position: Q3 2026 in Review

BFC Planning, Inc. reduced its CRISPR Therapeutics (CRSP) stake by 35% in Q3 2026, selling an estimated $58.7K and leaving 2,018 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1183.

BFC Planning, Inc. first reported a position in CRSP in Q3 2024 and has held it in 9 quarters since. The position peaked at $169K in Q2 2026. 413 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

BFC Planning, Inc. held 2,018 shares of CRISPR Therapeutics worth $112K as of Q3 2026.
BFC Planning, Inc. sold 1,088 CRISPR Therapeutics shares in Q3 2026, an estimated $58.7K.
CRISPR Therapeutics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q3 2026, its #1183 holding.
BFC Planning, Inc. first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 9 quarters since.
BFC Planning, Inc.'s CRISPR Therapeutics position peaked at $169K in Q2 2026.
413 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on BFC Planning, Inc.'s 13F filing for Q3 2026, filed 13 Nov 2026.